FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ursula Paulus

Research Profile

Disorders

Hodgkin's Disease

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Germany

Living Beings

Physiology

Co-author Network

Publications

TOP 3
Christine Georgias; Andrea Grunow; Alexander May; Miriam Olderog; Ursula Paulus
Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
Peter Borchmann; Thomas Cerny; Volker Diehl; Bernd Dörken; Hans Theodor Eich; Michael Fuchs; richard greil; Heinz Haverkamp; Anthony D Ho; Christoph Huber; Lothar Kanz; Stefan W Krause; Jana Markova; Rolf-Peter Mueller; Hans-Konrad Mueller-Hermelink; Christoph Nerl; Ursula Paulus; Andreas Rank; Lenka Smardova; Andreas Engert
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Oana Brosteanu; Peggy Houben; Kristina Ihrig; Christian Ohmann; Ursula Paulus; Beate Pfistner; Gabriele Schwarz; Anke Strenge-Hesse; Ulrike Zettelmeyer
Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ursula Paulus (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Christine Georgias; Andrea Grunow; Alexander May; Miriam Olderog; Ursula Paulus
Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model.
Clinical trials (London, England) 2012;9(6):781-7.
2011: Peter Borchmann; Thomas Cerny; Volker Diehl; Bernd Dörken; Hans Theodor Eich; Michael Fuchs; richard greil; Heinz Haverkamp; Anthony D Ho; Christoph Huber; Lothar Kanz; Stefan W Krause; Jana Markova; Rolf-Peter Mueller; Hans-Konrad Mueller-Hermelink; Christoph Nerl; Ursula Paulus; Andreas Rank; Lenka Smardova; Andreas Engert
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4234-42.
2009: Oana Brosteanu; Peggy Houben; Kristina Ihrig; Christian Ohmann; Ursula Paulus; Beate Pfistner; Gabriele Schwarz; Anke Strenge-Hesse; Ulrike Zettelmeyer
Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
Clinical trials (London, England) 2009;6(6):585-96.
2007: Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3495-502.
2006: A Reis; P Ihle; Ursula Paulus; L V Ferber; V Diehl; R Walshe
Cost of illness of malignant lymphoma in Germany.
European journal of cancer care 2006;15(4):379-85.
2003: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Markus Loeffler
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
The New England journal of medicine 2003;348(24):2386-95.
2003: Markus Sieber; Henning Bredenfeld; Andreas Josting; T Reineke; Ulrich Rueffer; T Koch; R Naumann; Friederike Boissevain; Peter Koch; P Worst; M Soekler; Hans Theodor Eich; Hans Konrad Müller-Hermelink; Jeremy Franklin; Ursula Paulus; Jürgen Wolf; Andreas Engert; Volker Diehl
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1734-9.
2002: Jan-Peter Glossmann; Andreas Josting; Beate Pfistner; Ursula Paulus; Andreas Engert
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
Annals of hematology 2002;81(8):424-9.
2002: Markus Sieber; Hans Tesch; Beate Pfistner; Ulrich Rueffer; Bernd Lathan; Oana Brosteanu; Ursula Paulus; Tina Koch; Michael Pfreundschuh; Markus Loeffler; Andreas Engert; Andreas Josting; Jürgen Wolf; Dirk Hasenclever; Jeremy Franklin; Eckhart Duehmke; Axel Georgii; Klaus-Peter Schalk; Hartmut Kirchner; Gottfried Doelken; Reinhold Munker; Peter Koch; Richard Herrmann; richard greil; Anna Paola Anselmo; Volker Diehl
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):476-84.
2002: S Wiedenmann; Petra Schiller; Ursula Paulus; Jürgen Wolf
Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():84-5.
2001: Eckhart Dühmke; Jeremy Franklin; Michael Pfreundschuh; Susanne Sehlen; Normann Willich; Ursula Rühl; Rolf-Peter Müller; P Lukas; A Atzinger; Ursula Paulus; Bernd Lathan; U Rüffer; Markus Sieber; Jürgen Wolf; Andreas Engert; Axel Georgii; Susanne Staar; Richard Herrmann; M Beykirch; Hartmut Kirchner; A Emminger; richard greil; E Fritsch; Peter Koch; A Drochtert; Oana Brosteanu; Dirk Hasenclever; Markus Loeffler; Volker Diehl
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2905-14.
2001: Sascha Ansén; Andreas Engert; Jürgen Wolf; Markus Sieber; Ursula Paulus; Volker Diehl
[German Hodgkin's Lymphoma Study Group].
Onkologie 2001;24 Suppl 1():35-48.
2000: Jeremy Franklin; Ursula Paulus; D Lieberz; Kai Breuer; Hans Tesch; Volker Diehl
Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):617-23.
2000: D Lieberz; Michael Sextro; Ursula Paulus; Jeremy Franklin; Hans Tesch; Volker Diehl
How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of hematology 2000;79(2):73-8.
2000: Beate Pfistner; Ursula Paulus; Jan-Peter Glossmann; R Walshe; Hans Tesch; Volker Diehl
Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSG.
Studies in health technology and informatics 2000;77():399-403.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; J U Rueffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; E Duehmke; Axel Georgii; Markus Loeffler
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3810-21.
1998: TG Gerike; Ursula Paulus; Christopher S Potten; Markus Loeffler
A dynamic model of proliferation and differentiation in the intestinal crypt based on a hypothetical intraepithelial growth factor.
Cell proliferation 1998;31(2):93-110.
1998: Volker Diehl; Jeremy Franklin; Dirk Hasenclever; Hans Tesch; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Markus Sieber; JU Rüffer; Michael Sextro; Andreas Engert; Jürgen Wolf; R Hermann; L Holmer; U Stappert-Jahn; E Winnerlein-Trump; G Wulf; S Krause; A Glunz; K von Kalle; H Bischoff; C Haedicke; Eckhart Dühmke; Axel Georgii; Markus Loeffler
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S67-71.
1997: Reinhard von Wasielewski; M Mengel; Robert Fischer; Martin-Leo Hansmann; Klaus Hübner; Jeremy Franklin; Hans Tesch; Ursula Paulus; Martin Werner; Volker Diehl; Axel Georgii
Classical Hodgkin's disease. Clinical impact of the immunophenotype.
The American journal of pathology 1997;151(4):1123-30.
1997: Markus Loeffler; T Bratke; Ursula Paulus; Y Q Li; Christopher S Potten
Clonality and life cycles of intestinal crypts explained by a state dependent stochastic model of epithelial stem cell organization.
Journal of theoretical biology 1997;186(1):41-54.
1994: Y Q Li; Steve Roberts; Ursula Paulus; Markus Loeffler; Christopher S Potten
The crypt cycle in mouse small intestinal epithelium.
Journal of cell science 1994;107 ( Pt 12)():3271-9.
1993: Ursula Paulus; Markus Loeffler; J Zeidler; G Owen; Christopher S Potten
The differentiation and lineage development of goblet cells in the murine small intestinal crypt: experimental and modelling studies.
Journal of cell science 1993;106 ( Pt 2)():473-83.
1992: Ursula Paulus; Christopher S Potten; Markus Loeffler
A model of the control of cellular regeneration in the intestinal crypt after perturbation based solely on local stem cell regulation.
Cell proliferation 1992;25(6):559-78.
1988: Markus Loeffler; Christopher S Potten; Ursula Paulus; J Glatzer; S Chwalinski
Intestinal crypt proliferation. II. Computer modelling of mitotic index data provides further evidence for lateral and vertical cell migration in the absence of mitotic activity.
Cell and tissue kinetics 1988;21(4):247-58.
1988: Christopher S Potten; Steve Roberts; S Chwalinski; Markus Loeffler; Ursula Paulus
Scoring mitotic activity in longitudinal sections of crypts of the small intestine.
Cell and tissue kinetics 1988;21(4):231-46.